Home/Biosimilar Atlas/Trastuzumab/Biocad trastuzumab

Biocad trastuzumab

Trastuzumab biosimilar developed by Biocad, development code BCD-022. Reference product Herceptin.

Brands by market: Brand not published by CDSCO (India, import) ยท Commercial partner or holder: Biocad India (import)
FDAnot listed
EMAnot listed
CDSCOApr 2018permitted
EDEnot listed

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Biocad India Pvt Ltd
Pathway
Import and marketing permission
Approved
Apr 2018
Application or permission
Import permission
Indications as licensed
Neoadjuvant, adjuvant and metastatic HER2-positive breast cancer
Presentations
150 mg single-use and 440 mg multi-use vials
Source
S013
EDE

United Arab Emirates

Not listed by EDE.

Chronology

Sources

All trastuzumab biosimilars

Planning trastuzumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.